Sandoz Group Ltd · SIX:SDZ

Sandoz — Cowen Healthcare Conference 2015

23 slides from Sandoz's conference presentation, Mar 4, 2015

  1. Slide 1: Sandoz: Leading the way in high-quality generic medicines

    Slide 1: Sandoz: Leading the way in high-quality generic medicines

    Sandoz: Leading the way in high-quality generic medicines Peter Goldschmidt President, Head of North America, Sandoz, Inc. Boston, MA March 4, 2015

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer These materials contain forward-looking statements that can be identified by words such as “potential,” “expected,” “will,” “planned,” or similar terms, or by express or implied discussions regarding potential future revenues from any such products; potential shareholder returns or credit

  3. Slide 3: Agenda

    Slide 3: Agenda

    Agenda Sandoz overview Leading the way in differentiated products Making a world of difference 3 | Sandoz Company Presentation | March 2015 | Business Use Only

  4. Slide 4: Sandoz's Mission is focused on patients

    Slide 4: Sandoz's Mission is focused on patients

    Sandoz’s Mission is focused on patients “We will be the main provider of high-quality, affordable medicines, helping secure long-term access to healthcare for people around the world.” 4 | Sandoz Company Presentation | March 2015 | Business Use Only

  5. Slide 5: Sandoz is uniquely positioned within the worldwide Novartis Group

    Slide 5: Sandoz is uniquely positioned within the worldwide Novartis Group

    Sandoz is uniquely positioned within the worldwide Novartis Group1 Environment Patient needs Innovative medicines Novartis Pharmaceuticals Affordable Broad options range of health- care options Self-care Alcon Prevention Sandoz 1 GSK transaction closed as of March 2, 2015 5 | Sandoz Company Presenta

  6. Slide 6: Sandoz is a global leader in generics

    Slide 6: Sandoz is a global leader in generics

    Sandoz is a global leader in generics Top Generic companies, 2014 sales1 USD million 10,810 9,562  Sell products in over 160 countries 6,747  Over 26,000 employees worldwide  Portfolio of >1,100 compounds 6,459 and >24,000 SKUs 2,496  Rich pipeline with >800 projects 2,395  Biosimilars pioneer

  7. Slide 7: Sandoz products are sold in more than 160 countries worldwide

    Slide 7: Sandoz products are sold in more than 160 countries worldwide

    Sandoz products are sold in more than Sandoz fulltime presence 160 countries worldwide Sales through local partners 7 | Sandoz Company Presentation | March 2015 | Business Use Only

  8. Slide 8: Sandoz had solid performance in 2014

    Slide 8: Sandoz had solid performance in 2014

    Sandoz had solid performance in 2014 2014 Sandoz Financial Results USD million at actual rates, variances in CC vs. 2013 THIRD-PARTY 9,562 +7% SALES CORE OPERATING 1,571 +7% INCOME Core ROS 16.4% OPERATING 1,088 +14% INCOME ROS 11.4% 8 | Sandoz Company Presentation | March 2015 | Business Use Only

  9. Slide 9: Sandoz continues to outperform the global market

    Slide 9: Sandoz continues to outperform the global market

    Sandoz continues to outperform the global market 2014 FY total net sales growth vs. PY Percent in constant currency Market1 Sandoz Western Central & Europe3 Eastern Europe 4 2 5 -1 North America 13 Germany 1 0 Asia-Pacific -1 7 11 Middle East & Latin America2 Africa 20 5 4 6 1 Net market growth vs.

  10. Slide 10: Sandoz showed strongest growth in the US market

    Slide 10: Sandoz showed strongest growth in the US market

    2014: Sandoz showed strongest growth in the US market 2014 US Gx market (prescriptions) Top 10 companies Generics Market prescriptions share Prescription growth vs. prior year Company million Percent Percent Teva 471 13.4 -4.6 Mylan 337 9.6 -7.9 Sandoz 254 7.2 21.8 Actavis 233 6.6 -9.6 Qualitest 216

  11. Slide 11: Sandoz is now #1 in Europe!

    Slide 11: Sandoz is now #1 in Europe!

    Sandoz is now #1 in Europe! Net generic sales in Europe1 incl. OTC USD million; as reported in company financials 1,150 1,100 1,050 1,000 950 900 850 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2012 2013 2014 1 Western Europe, including Germany 11 | Sandoz Company Presentation | March 2015 | Business Use

  12. Slide 12: Sandoz is focused on key emerging growth markets

    Slide 12: Sandoz is focused on key emerging growth markets

    Sandoz is focused on key emerging growth markets Presence in emerging markets1 – Sandoz vs. key global competitors Percentage of total generic sales, 20142 26 14 7 1 1 Emerging Growth Markets comprise all markets except the US, Canada, Western Europe, Japan, Australia and New Zealand 2 For Sandoz, n

  13. Slide 13: Sandoz has a rigorous global Quality Commitment

    Slide 13: Sandoz has a rigorous global Quality Commitment

    Sandoz has a rigorous global Quality Commitment, which is focused on patients One global Quality standard across Novartis Group • Patients are at the center of everything we do, and the heart of our Quality commitment • Quality is critical for sustainable business performance and growth • We work cl

  14. Slide 14: Sandoz has a diverse and highly experienced global leadership team

    Slide 14: Sandoz has a diverse and highly experienced global leadership team

    Sandoz has a diverse and highly experienced global leadership team Global Head of Sandoz Richard Francis Exec. Assistant: Anne Verwohlt Strat. Assistant to Global Head of Sandoz Aarthi Ramarathnam Functions Commercial Operations Finance/IT Product Development Asia Pacific (APAC) Anti-Infectives BU K

  15. Slide 15: Agenda

    Slide 15: Agenda

    Agenda Sandoz overview Leading the way in differentiated products Making a world of difference 15 | Sandoz Company Presentation | March 2015 | Business Use Only

  16. Slide 16: Future patent expiries will shift towards differentiated products

    Slide 16: Future patent expiries will shift towards differentiated products

    Future patent expiries will shift towards differentiated products, validating the Sandoz strategy Sales of products in the year prior to patent expiry by year of patent expiry USD billion 52 52 43 Differentiated Standard 35 37 30 32 32 27 23 19 20 20 15 12 13 13 13 6 6 7 4 5 2 2 2 1 1 1993 1998 2002

  17. Slide 17: Sandoz has an industry-leading range of differentiated product technologies

    Slide 17: Sandoz has an industry-leading range of differentiated product technologies

    Sandoz has an industry-leading range of differentiated product technologies Biosimilars Injectables Ophthalmics Patches/ transdermals/ Dermatology Lyophilization thin films Inhalers Cytotoxics API Innovative solid Implants Hormones formulations 17 | Sandoz Company Presentation | March 2015 | Busines

  18. Slide 18: Differentiated products already account for nearly half of the Sandoz global portfolio

    Slide 18: Differentiated products already account for nearly half of the Sandoz global portfolio

    Differentiated products already account for nearly half of the Sandoz global portfolio Portfolio split between standard and differentiated products Percentage of total sales Differentiated products1 32% 45% Standard generics 68% 55% 2008 2014 1 Differentiated comprises all difficult-to-make products

  19. Slide 19: Biosimilars: Sandoz is the uncontested global #1

    Slide 19: Biosimilars: Sandoz is the uncontested global #1

    Biosimilars: Sandoz is the uncontested global #1 Highest market share globally1 Leading brands Strong pipeline 2014 global biosimilars market share 2 (%) 2014 global biosimilars Molecules in Phase III position in their categories3 clinical trial / registration prep phase Others 8% #1 18% #1 57% 17%

  20. Slide 20: Innovation: Novel AirFluSal Forspiro respiratory inhaler rolled out

    Slide 20: Innovation: Novel AirFluSal Forspiro respiratory inhaler rolled out

    Innovation: Novel AirFluSal® Forspiro® respiratory inhaler rolled out across Europe and beyond  Now approved in 19 countries 1  Launched in Germany, Sweden, Denmark, Norway, Bulgaria, South Korea and Mexico  Innovative new inhaler, developed in close collaboration with patients 1 In order: DEN, G

  21. Slide 21: Agenda

    Slide 21: Agenda

    Agenda Sandoz overview Leading the way in differentiated products Making a world of difference 21 | Sandoz Company Presentation | March 2015 | Business Use Only

  22. Slide 22: Novartis reached 1.2 billion patients in 2014

    Slide 22: Novartis reached 1.2 billion patients in 2014

    Novartis reached 1.2 billion patients in 20141 1 Novartis calculation, based on internal financial & external medical data; products sold to the markets translated into a course of therapy 22 | Sandoz Company Presentation | March 2015 | Business Use Only

  23. Slide 23: Sandoz business model drives Corporate Responsibility across four key pillars

    Slide 23: Sandoz business model drives Corporate Responsibility across four key pillars

    Sandoz business model drives Corporate Responsibility across four key pillars Sandoz Corporate Responsibility Access People & Environmental Business Communities Sustainability Conduct Grants, Donations & Sponsoring across all pillars 23 | Sandoz Company Presentation | March 2015 | Business Use Only

Source: Internet Archive copy of novartis.com

More decks from Sandoz Group Ltd

All 25 Sandoz decks